Taken together, these data suggest that chronic-therapy (ADT)-in-hypoxia may select prostate cancer cells capable of displaying androgen/AR-pathway independence and therapy resistance in hypoxia in vitro and in xenograft tumors in vivo. The gene discussed is AR; the disease is prostate cancer.